Low‐Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non‐Diabetic Japanese Adults
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71162 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Michitaka Amioka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Hiroshima Cardiovascular Clinic, Hiroshima, Japan. Hauptthemen laut MEDLINE: Tirzepatide, Obesity, Anti-Obesity Agents. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Obesity is a major global health issue. While tirzepatide demonstrates robust weight reduction in clinical trials, data comparing low maintenance doses (2.5 vs. 5 mg) in non‐diabetic adults with obesity remain limited. This study evaluated the comparative efficacy and safety of 2.5 versus 5 mg tirzepatide combined with lifestyle intervention.
Methods
This multicentre, prospective, non‐randomised cohort study enrolled non‐diabetic Japanese adults (18–65 years) with BMI ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with comorbidities. Patients initiated tirzepatide at 2.5 mg weekly; after 4 weeks, the dose was maintained at 2.5 mg or increased to 5 mg based on shared decision‐making. All participants received standardised dietary and exercise counselling. The primary outcome was the proportion achieving BMI < 25 kg/m 2 or > 15% body weight reduction at 6 months.
Results
Of 112 participants analysed (58 on 2.5 mg, 54 on 5 mg), baseline characteristics were well balanced (mean BMI 30.8 kg/m 2 ). At 6 months, the primary outcome was achieved in 62.1% of the 2.5 mg group and 63.0% of the 5 mg group (HR 0.93, 95% CI 0.58–1.49; p = 0.772). Mean percent weight loss was −15.3% and −16.1%, respectively ( p = 0.563), with similar reductions in BMI, skeletal muscle mass, and bone mass. Adherence to dietary therapy was excellent in both groups (96.4%), while exercise adherence was 37.5%. Adverse events were more frequent with 5 mg (50% vs. 35%), primarily gastrointestinal symptoms.
Conclusion
In non‐diabetic Japanese adults with obesity, 2.5 and 5 mg tirzepatide combined with lifestyle modification yielded similar weight loss at 6 months, with better tolerability at the lower dose. These findings support the potential utility of low‐dose tirzepatide strategies in real‐world practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Hiroshima Cardiovascular Clinic, Hiroshima, Japan.
- Department of Cardiovascular Medicine, Onomichi General Hospital, Hiroshima, Japan.
- Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
ORCID-Profile: Michitaka Amioka
Zitieren
APA
Amioka, M., Amioka, H., Kinoshita, H., Sairaku, A., & Nakano, Y. (2026). Low‐Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non‐Diabetic Japanese Adults. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71162
Vancouver
Amioka M, Amioka H, Kinoshita H, Sairaku A, Nakano Y. Low‐Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non‐Diabetic Japanese Adults. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71162
BibTeX
@article{Amioka2026,
author = {Amioka, Michitaka and Amioka, Hideyo and Kinoshita, Hiroki and Sairaku, Akinori and Nakano, Yukiko},
title = {Low‐Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non‐Diabetic Japanese Adults},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71162}
}
EUVIMED